The latest news from the global pharmaceutical industry. Below you will find news and information to keep you up-to-date with what is happening in your industry. Coverage includes regulatory approvals, recall announcements, mergers and acquisitions, personnel news and appointments, new facility and facility expansion updates, collaborations and agreements, and financial updates.
The FDA has approved KANJINTI™ for all approved indications of the reference product, Herceptin® for HER2-overexpressing adjuvant and metastatic ...
read more
Cellular Biomedicine Group has initiated its Phase I Clinical Trial of anti-CD20 Chimeric Antigen Receptor T-cell (CAR-T) targeting anti-CD19 treated,...
read more
Therapix Biosciences announced interim results from its Phase IIa clinical study at Assuta Medical Center in Israel, suggesting that THX-110, a ...
read more
Atox Bio announced BARDA has exercised the next option on a performance-based contract with for the development of Reltecimod in patients with ...
read more
Kleo announced CD38-ARM will be its first product candidate to move into the clinic with anticipated human studies to commence in 2020.
read more
Denovo Biopharma has licensed ORM-12741 from Orion Corporation.
read more
Sophiris Bio has received formal scientific advice from the EMA regarding a proposed design of a Phase 3 clinical trial to evaluate topsalysin.
read more
ReNetX Bio has announced the FDA has allowed the Company's IND application for its lead drug candidate, fusion protein AXER-204.
read more
The FDA expanded the indication for Symdeko tablets for treatment of pediatric patients ages 6 years and older with cystic fibrosis who have certain ...
read more
Glenmark has received a CRL from the FDA for Ryaltris™ (olopatadine hydrochloride [665 mcg] and mometasone furoate [25 mcg]), Nasal Spray.
read more
CBM BioPharma announced the USPTO has issued a Notice of Allowance and Issue Fee Due in CBM's patent application related to the treatment of ...
read more
AstraZeneca Pharmaceuticals
AstraZeneca announced positive OS results from the Phase III CASPIAN trial with IMFINZI in 1st-line extensive-stage small cell lung cancer.
read more
Appili announced the United States DOD Congressionally Directed Medical Research Programs, PRMRP has completed the contract awarding the Company a $3....
read more
NeuroVive announced initiation of the second part in its ongoing Phase Ia/b clinical study with KL1333, its candidate drug for chronic treatment of ...
read more
BiondVax announced the first participants in the second cohort of the pivotal, clinical efficacy, Phase 3 trial of the M-001 universal flu vaccine ...
read more